Can a diabetes drug tame blood sugar swings after bariatric surgery?
NCT ID NCT07515391
First seen Apr 09, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This phase 2 trial tests whether dapagliflozin, a diabetes drug, can reduce dangerous blood sugar highs and lows in people who have had bariatric surgery. The study will enroll 30 participants, both with and without type 2 diabetes, and monitor glucose levels continuously for 12 weeks. The goal is to see if the drug improves overall glucose control and reduces hypoglycemia and hyperglycemia episodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY CANDIDATE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dasman Diabetes Institute
Kuwait City, Dasman, 15462, Kuwait
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug that helps the kidneys remove extra sugar through urine)
What this could lead to
If it works, this could show that dapagliflozin helps stabilize blood sugar levels after bariatric surgery, potentially improving diabetes management.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug also carries risks like dehydration or urinary infections.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.